SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is experiencing extreme volatility following news that its flagship NHS-Galleri cancer screening trial missed its primary endpoint, despite beating Q4 revenue and EPS estimates. While some in the community see the massive price drop as an overreaction to misunderstood trial results, others are concerned about the long-term viability and potential for further decline.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending amidst investor anticipation for its conference and financial results, fueled by strong underlying sales growth from its products and the Alani Nu integration. Nevertheless, community sentiment is sharply divided, with ongoing discussions scrutinizing management's communication and the implications of Pepsi's deepening strategic involvement, including persistent buyout speculation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following news of a proposed $100 million public stock offering and a $100 million royalty funding agreement, sparking intense community debate. While many shareholders express frustration over perceived dilution and management's strategy, supporters argue these moves are crucial to secure long-term financing and maintain independence for advancing its clinical pipeline toward potential commercialization.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending amid community discussions regarding its latest Q4 earnings, which showed strong IBSRELA revenue growth offset by increased strategic investments, and recent news of a patent extension until 2042 for its key products. Additionally, investors are actively weighing the initiation of a new Phase 3 trial for IBSRELA and ongoing rumors of a potential acquisition by Zydus Lifesciences, with many expressing frustration over the stock's perceived undervaluation despite these developments.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is trending following investor concerns about its path to profitability and weak guidance shared during its recent earnings call, sparking community debate over the 'buy now, pay never' business model amidst significant stock price drops.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending after its Q4 earnings surpassed analyst expectations with strong revenue, EPS, and record free cash flow. However, investor sentiment is mixed, as many express frustration over the muted stock reaction, citing concerns about lower production guidance and higher projected costs for 2026.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is trending due to circulating rumors of a strategic OpenAI partnership for monetizing ChatGPT, fueling a robust rebound and intense debate among investors. This comes as the company navigates a competitive ad-tech landscape, with many bulls citing strong underlying earnings as a reason to buy the dip.

Copart, Inc. engages in the provision of online auctions and vehicle remarketing services. The firm offers vehicle sellers a full range of services to process and sell vehicles primarily over the internet through Virtual Bidding Third Generation Internet auction-style sales technology. It sells vehicles principally to licensed vehicle dismantlers, rebuilders, repair licensees, used vehicle dealers, exporters and at certain locations, and the public. The company’s services include online seller access, salvage estimation services, estimating services, end-of-life vehicle processing, virtual insured exchange, transportation services, vehicle inspection stations, on-demand reporting, DMV processing, and vehicle processing programs. It operates through the United States and International segments. The company was founded by Willis J. Johnson in 1982 and is headquartered in Dallas, TX.

Copart, Inc.

Copart is trending as investors assess its recent mixed Q1 earnings, yet the community highlights resumed share buybacks and the company's robust operational efficiency driven by AI integration, leading many to view it as an undervalued long-term opportunity in the salvage auction market.

Sprouts Farmers Market, Inc. engages in the operation of healthy grocery stores. The firm specializes in fresh, natural and organic products. Its products include fresh produce, bulk foods, vitamins and supplements, grocery, meat and seafood, deli, bakery, dairy, frozen foods, body care and natural household items. The company was founded by Stan Boney, Shon Alexander Boney, and Kevin K. Easler on July 11, 2002 and is headquartered in Phoenix, AZ.

Sprouts Farmers Market Inc

Sprouts Farmers Market is trending due to a significant stock decline after its Q3 earnings report, which, despite an EPS beat, included a revenue miss and cautious Q4 guidance attributed to softer consumer demand. The community is sharply divided, with bulls emphasizing strong fundamentals, a substantial share repurchase program, and store expansion as a buying opportunity, while bears highlight slowing comparable sales and valuation concerns.

Akamai Technologies, Inc. engages in the provision of cloud services for delivering, optimizing, and securing content and business applications over the Internet. Its products include security, web performance, media delivery, and network operator. The company was founded by Frank T. Leighton, Jonathan Seelig, Randall S. Kaplan, and Daniel M. Lewin on August 20, 1998 and is headquartered in Cambridge, MA.

Akamai Technologies Inc

Akamai Technologies is trending following a mixed earnings report, where strong Q4 performance and growth in security and cloud solutions were eclipsed by lower-than-expected forward guidance, fueling community debate on its AI edge computing pivot amidst a competitive landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xeris Biopharma (NASDAQ:XERS) Trading Down 9.3% - Should You Sell?

Xeris Biopharma (NASDAQ:XERS) Trading Down 9.3% - Here's Why...

Xeris Biopharma Holdings, Inc. $XERS Shares Sold by CenterBook Partners LP

CenterBook Partners LP decreased its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 56.2% during the third quarter, according to the company in its most recent...

Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight analysts that are covering the firm, MarketBeat.com...

Y Intercept Hong Kong Ltd Lowers Holdings in Xeris Biopharma Holdings, Inc. $XERS

Y Intercept Hong Kong Ltd decreased its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 75.6% during the third quarter, according to the company in its most recent filing...

Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 16,667 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an...

Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 15,000 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Kevin Mcculloch sold 15,000 shares of the business's stock in a transaction on Thursday, January 8th. The shares were sold at an...

Xeris Biopharma (NASDAQ:XERS) Shares Gap Up - Here's Why

Xeris Biopharma (NASDAQ:XERS) Shares Gap Up - What's Next...

John Patrick Shannon, Jr. Sells 24,907 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider John Patrick Shannon, Jr. sold 24,907 shares of Xeris Biopharma stock in a transaction that occurred on Monday, January 5th. The...

Xeris Biopharma (NASDAQ:XERS) Insider Sells $176,341.56 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider John Patrick Shannon, Jr. sold 24,907 shares of the firm's stock in a transaction that occurred on Monday, January 5th. The...

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

XERS
Xeris Biopharma Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XERS News

XERSXeris Biopharma Holdings Inc